Tagged with OP

Global First published in the November 2025 issue of DIA’s Global Forum, this article by Victoria Gamermanusa (RWD Insights) tackles one of rare disease research’s toughest dilemmas: how to run credible efficacy trials when patient numbers make traditional statistics unworkable. She charts how AI, Bayesian methods, transfer learning, and synthetic data…

UK First published in the November 2025 edition of DIA’s Global Forum, this piece by Jane Morrin O’Rourke, Naho Yamazaki, Becky Purvis (HRA) and Mandy Budwal-Jagait, Jason Wakelin-Smith and Kingyin Lee (MHRA) dives into one of the UK’s most urgent research challenges: how to make clinical trials genuinely inclusive. The authors…

China This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Lilly’s US$345M AI-driven BsAb licensing deal with XtalPi, IVACTA’s RMB 100M fundraising for in vivo CAR-T therapies, Vigonvita’s HKD 5.873B IPO with 4,974x oversubscription, and Neurocrine’s US$881M global licensing of TransThera’s NLRP3 inhibitors. Clinical breakthroughs feature HighTide’s positive Phase…

Germany The latest news from German pharma, including looming drug pricing reform, Boehringer Ingelheim’s EUR 640 million acquisition of a Kyowa Kirin autoimmune drug, and BioNTech’s updated revenue guidance. Also covered are Merck KGaA’s tie-up with JSR Life Sciences for its chromatography business, Bayer’s 12,000 layoffs, and STADA’s potential IPO.  …

China This week’s China healthcare roundup from PharmaBoardroom content partner Selesta highlights Innovent’s record-breaking US$11.4 billion BsAb and ADC partnership with Takeda, DualityBio’s plans for a STAR Market IPO after positive HER2 ADC Phase III data, Biokin’s US$250 million milestone payment from BMS and HKEX IPO approval, and Haixi Pharma’s 36%…

France Under Laurence Rodriguez’s leadership, GenSight Biologics is charting a bold path forward after a period of reset, advancing groundbreaking gene therapies for rare ophthalmic and mitochondrial diseases. She reflects on rebuilding the organisation, preparing a pivotal Phase III study for the gene therapy GS010/LUMEVOQ, and shaping the future of optogenetic…

France Curium is redefining how radiopharmaceuticals are developed, manufactured, and delivered to patients worldwide. Under the leadership of Ciril Faia, Curium International is advancing a new generation of diagnostic and therapeutic innovations, with particular focus on prostate cancer and neuroendocrine tumours (NET). Through sustained investment in talent, infrastructure, and its newly…

China This week’s China healthcare roundup from PharmaBoardroom content partner Selesta highlights Kite Pharma’s US$1.64B in vivo CAR-T deal with Pregene, Xuanzhu Biopharma’s HKEX debut with a 172% grey market premium, Hansoh’s US$1.53B CDH17 ADC licensing to Roche, and Leads Biolabs’ US$1B autoimmune drug deal with Dianthus. Biokin secured a record…

France Genopole stands as one of France’s leading bioclusters, seamlessly integrating world-class research, entrepreneurship, and industrial engagement to support over 80 companies across health and the bioeconomy. Under Gilles Trystram’s leadership, the cluster nurtures innovation from start-up creation to scaling, leveraging strategic partnerships with institutions like Université Paris-Saclay and specialised platforms…

Switzerland The first company to bring a treatment for metabolic dysfunction-associated steatohepatitis (MASH) to market, Madrigal Pharmaceuticals is redefining how the world tackles fatty liver disease. From its new European base in Zug, the firm is building an entirely new therapeutic category while spearheading one of the most ambitious global launches…

France Pascal Houdayer, recently appointed CEO and the first non-family investor of Boiron, brings three decades of global leadership experience to one of France’s most iconic healthcare enterprises. In this conversation, he reflects on Boiron’s evolution from a pioneer in homeopathy to a global advocate of integrative health, its diversification into…

UK Originally published in the October 2025 edition of DIA’s Global Forum magazine, this article — authored by Mandy Budwal-Jagait, Kingyin Lee, Maria Urdaneta-Abate, Hedwig Ganguly, Rachel Mead, and Louisa Obillo of the UK Medicines and Healthcare products Regulatory Agency (MHRA), together with Catherine Blewett of the Health Research Authority (HRA)…